Evaluating Non-Invasive Brain Stimulation Using rTMS for Walking Disability in Multiple Sclerosis Patients with Spastic Paraparesis
Led by Clinique Neuro-Outaouais · Updated on 2026-10-22
70
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the impact of repetitive Transcranial Magnetic Stimulation rTMS on walking ability in people with Multiple Sclerosis MS who have spastic paraparesis and moderate walking disability. The study aims to measure changes in overall disability, walking endurance, quality of life, and brain activity patterns using EEG in patients with MS. This interventional trial is led by Clinique Neuro-Outaouais and uses a randomized, parallel design with triple masking.
Participants will receive rTMS treatment using magnetic pulses targeting specific brain areas. The active treatment group will get 100% magnetic pulse intensity, while the comparison group will receive sham rTMS at 10% intensity. The treatment is scheduled daily, five times a week, for 6 consecutive weeks. After a 6-week break, all participants will then receive active rTMS treatment for another 6 weeks.
During the study, participants will be assessed using walking tests including the Timed 25-Foot Walk Test T25FWT and the Six Minute Walk Test 6MWT, along with quality of life questionnaires MSQoL. The study will also monitor EEG parameters to assess neural synchrony. The primary outcome will be measured at 18 weeks, with secondary outcomes assessed at 12 weeks. Total participation will cover the treatment and evaluation periods, with safety and compliance monitored throughout.
CONDITIONS
Brief Title
Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis
Research Team
F
Francois Jacques, Neurologist
I
Ibrahim Sangare, Nurse
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with Multiple Sclerosis according to the revised 2017 McDonald Criteria
Expanded Disability Status Scale (EDSS) score between 3.0 and 6.5 with a pyramidal functional system score of 3.0 or higher
Neurologically stable with no medication changes or relapse for at least 30 days prior to screening
Allowed to continue fampridine if started more than 30 days before screening; no new stimulants or spasticity treatments allowed during the study
No changes in disease modifying therapy for at least 3 months prior to screening
Ability and willingness to perform walking tests and comply with study protocol as judged by the investigator
You will not qualify if you...
Presence of other neurological disorders that could add to disability during the study period
Significant cardiovascular, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease that may preclude participation
Pregnant, breastfeeding, or intending to become pregnant during the study
Previous rTMS therapy for any reason
Contraindications to rTMS such as implanted CNS devices or pacemakers
Any condition deemed by the investigator to make the patient unsuitable for the study
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 18 weeks total (including break)
Participants will receive either active rTMS or sham stimulation daily, five times a week, for 6 weeks. After a 6-week break, all participants will receive active rTMS for another 6 weeks.
Daily visits, 5 days per week
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Balance, Gait, and Motion Analysis in Adults with Multiple Sclerosis Using Vicon System
Validating Patient-Collected Selfie Videos to Measure Function in Multiple Sclerosis
Comparison of 3D Optimized WMN MPRAGE and Conventional MRI Sequences for Detecting Spinal Cord Lesions in Adults with Multiple Sclerosis
Phase 1 Study Comparing IVL3004 and IVL4002 to Vivitrol4 Naltrexone Long-Acting Injection in Healthy Adult Males
Long-Term Follow-Up Study for Adults Previously Treated with KYV-101 CAR T-Cell Therapy
Combining Cognitive Rehabilitation with Exercise to Improve Learning and Memory in Adults with Multiple Sclerosis
Randomized Study of Oral PRO-1562 for Safety and Remyelination in Healthy Adults and Patients With Relapsing Multiple Sclerosis and Chronic Optic Neuropathy
Study of a Flavonoid-rich Mediterranean Diet to Support People with Multiple Sclerosis Aged 30 to 65
Comparing Effectiveness and Costs of Kesimpta Ofatumumab Versus Ocrevus Ocrelizumab in Multiple Sclerosis A Retrospective Real-World Study
Evaluating Pregnancy and Infant Outcomes With BRIUMVI Ublituximab in People With Multiple Sclerosis